Efficacy News and Research

RSS

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.

16 Jun 2011

Adaptimmune melanoma trial opening

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.

16 Jun 2011

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

16 Jun 2011

Tulane University, VA grant IRB approval for new TIGR Matrix clinical trial in hernia repair

Novus Scientific today announced that Tulane University School of Medicine and Department of Veterans Affairs have granted IRB approval to a new trial: A Study Evaluating Efficacy of TIGR® Matrix Surgical Mesh used in Elective Open Inguinal Hernia Repair.

16 Jun 2011

Large trial of tenofovir gel for women set to begin in South Africa

A 24-month clinical trial looking at the effectiveness of tenofovir gel use among women to reduce the risk of HIV infection is set to begin in South Africa in late July or early August, the Mail & Guardian reports.

16 Jun 2011

Evidence-based practice guidelines for prevention and treatment of frostbite

Frostbite can be a minor injury or a life-threatening condition. In the June issue of Wilderness & Environmental Medicine, a panel of experts has published evidence-based practice guidelines issued by the Wilderness Medical Society (WMS) for the prevention and treatment of frostbite to guide clinicians and disseminate knowledge about best practices.

16 Jun 2011

MRE reduces ionizing radiation exposure, detects Crohn's disease as reliably as CT

A new study from Rhode Island Hospital has found that MR enterography (MRE) without the use of an anti-peristaltic agent were as reliable as CT enterography (CTE) in determining the presence of Crohn's disease.

16 Jun 2011

Antibiotics overprescribed for in home-care patients

A study of Canadian home-care patients suggests doctors may be overprescribing antibiotics for patients receiving ongoing medical care at home.

16 Jun 2011

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Results of a Phase 2 study sponsored by Somnus Therapeutics, Inc., add further evidence supporting the efficacy and safety of a novel bedtime therapeutic that addresses a major underserved need of insomnia patients: maintaining sleep.

16 Jun 2011

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy.

15 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

FDA issues final rulemaking on testing and labeling of sunscreen products

"FDA's recognition today of the important role sunscreens play in protecting the public not only from sunburn but also from skin cancer and premature aging due to the sun is a very significant victory for public health. The role of UV rays in causing skin damage and the role of sunscreens in protecting against this sun damage are widely acknowledged within the medical and scientific communities, and we're very pleased the agency has taken this critical step.

15 Jun 2011

Leukothera effectively treats psoriasis in humanized mouse xenograft transplantation model

Psoriasis is a persistent, long-lasting chronic skin disease affecting 2-3 percent of the world's population or more than 125 million individuals. For some, it is just a nuisance. For others, it is disabling.

15 Jun 2011

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

A type of virus known as the human reovirus possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation, while leaving the body's normal cells alone.

15 Jun 2011

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

Meda presents new positive results from a Phase-III clinical trial of Dymista at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in Istanbul, Turkey.

15 Jun 2011

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

Cancer diagnostics company Biomoda, Inc. received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath assay to include patient response to cancer therapy during the treatment phase of the disease.

15 Jun 2011

PDR launches new online network to collect, distribute adverse drug events in the U.S.

PDR Network and its partners today announced the launch of a new online network to collect and distribute adverse drug events in the United States.

From Physicians' Desk Reference (PDR) 15 Jun 2011

Interventions can buffer caregivers from stresses faced in providing care to terminally ill patients

Interventions can buffer caregivers of terminally ill patients from the significant stresses they face in providing care to a loved one, a new evidence review finds.

15 Jun 2011

Sangart commences MP4OX Phase 2b study in acute traumatic injury

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock.

15 Jun 2011

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it successfully completed patient enrollment in its phase II Contrast-Induced Acute Kidney Injury study with its oral drug candidate CRMD001.

14 Jun 2011

Efficacy News and Research

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Adaptimmune melanoma trial opening

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

Tulane University, VA grant IRB approval for new TIGR Matrix clinical trial in hernia repair

Large trial of tenofovir gel for women set to begin in South Africa

Evidence-based practice guidelines for prevention and treatment of frostbite

MRE reduces ionizing radiation exposure, detects Crohn's disease as reliably as CT

Antibiotics overprescribed for in home-care patients

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Galectin strengthens cancer drug patent portfolio in Europe

FDA issues final rulemaking on testing and labeling of sunscreen products

Leukothera effectively treats psoriasis in humanized mouse xenograft transplantation model

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

PDR launches new online network to collect, distribute adverse drug events in the U.S.

Interventions can buffer caregivers from stresses faced in providing care to terminally ill patients

Sangart commences MP4OX Phase 2b study in acute traumatic injury

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News